Assessing the benefits of rosiglitazone in women with polycystic ovary syndrome through its effects on insulin-like growth factor 1, insulin-like growth factor-binding protein-3 and insulin resistance: a pilot study. (2012). Clinics, 67(3), 283-287. https://doi.org/10.6061/clinics/2012(03)14